Table 1: Baseline clinical characteristics of stable hemodialysis patients with preserved left ventricular ejection fraction.

cTnT Tertiles for trend
Lower (cTnT 0.02 ng/mL, )Middle (0.02 < cTnT 0.042 ng/mL, )Upper (cTnT 0.042 ng/mL, )

Age (years) 0.27
Male, (%)11 (37%)9 (31%)12 (42%)0.71
BMI (kg/m2) 0.15
Kt/v 0.30
IDWG, (kg) 0.60
IDWG, (%) 0.98
Hemodialysis duration (years)6.5 (4, 9)4.4 (2, 9.9)4 (1.8, 6.4)0.31
SBP (mmHg) 0.93
DBP (mmHg) 0.44
Heart rate 0.94
Prevalent CAD8 (27%)11 (38%)12 (41%)0.46
Diabetes mellitus7 (23%)16 (55%)22 (76%)<0.001*
Hypertension27 (90%)25 (86%)25 (86%)0.85
LV hypertrophy#28 (93%)27 (93%)27 (93%)0.95
ACEI/ARB17 (57%)18 (62%)13 (45%)0.40
-Blocker15 (50%)11 (38%)15 (52%)0.40
CCB15 (50%)17 (59%)18 (62%)0.48
Statin6 (20%)4 (14%)5 (17%)0.94
Calcium (mg/dL) 0.26
Phosphate (mg/dL) 0.19
Albumin (g/dL) 0.21
Cholesterol (mg/dL) 0.55
hsCRP (mg/dL)0.26 (0.14, 0.63)0.66 (0.18, 0.99)0.45 (0.19, 1.95)0.12
IL-6 (pg/mL)9.5 (7.3, 16.3)9.7 (6.9, 13.7)10.6 (6.3, 19.1)0.85
PICP (ng/mL) 0.34

Continuous data are expressed as the mean ± standard deviation or the median (25th and 75th percentiles); categorical data are expressed as the number (percentage). A nonparametric Kruskal-Wallis test was used for nonnormally distributed data.
; #LV hypertrophy was diagnosed by echocardiography.
Abbreviations: ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II-receptor blocker; BMI: body mass index; CAD: coronary artery disease; CCB: calcium channel blocker; cTnT: cardiac troponin T; DBP: diastolic blood pressure; hsCRP: high-sensitivity C-reactive protein; IDWG: interdialytic weight gain; IL: interleukin; Kt/V: an indicator of dialysis adequacy ( : urea clearance; : dialysis time; : urea distribution volume); LV: left ventricle; PICP: procollagen type I C-terminal peptide; SBP: systolic blood pressure.